Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS) (NCT07247058)
Isturisa in Management of Mild Autonomous Cortisol Secretion (MACS)
🩺 Plain-English Summary (8th-Grade Level)
To characterize the impact of Isturisa on clinical features and comorbidities associated with MACS. The investigators hypothesize that patients treated with Isturisa will exhibit significantly better metabolic indicators (such as fasting glucose, HbA1c, and lipid profile), blood pressure, weight, body composition and bone mineral density than at Baseline. The investigators also assess the effect of Isturisa on quality of life and psychological symptoms in patients with MACS. The investigators hypothesize that treatment with Isturisa will lead to significant improvements in quality-of-life scores and reductions in depression scores compared to Baseline.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (8 items).
Location: Johns Hopkins University School of Medicine — Baltimore, Maryland
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Known diagnosis of Cushing's syndrome or overt hypercortisolism.
- Current or recent (within 3 months) treatment with glucocorticoids or medications affecting cortisol production (e.g., ketoconazole, metyrapone).
- Severe hepatic impairment or renal failure.
- Pregnancy or breastfeeding.
- Known allergy or contraindication to osilodrostat (Isturisa).
- Participation in another interventional clinical trial within the last 30 days.
- Any medical or psychiatric condition that, in the investigator's judgment, may interfere with study participation or safety.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- Johns Hopkins University School of Medicine — Baltimore, Maryland
📞 Contact the Study Coordinator
Phone: (667) 208-8367
Email: pjabbar1@jh.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Mild Autonomous Cortisol Secretion (MACS)
- IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion — Dallas, Texas
- Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion — Pittsburgh, Pennsylvania
- Detecting Mild Autonomous Cortisol Secretion in Patients With Adrenal Incidentaloma — Cleveland, Ohio
Explore by condition: All Mild Autonomous Cortisol Secretion (MACS) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.